Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005 Jul 15;309(5733):476-81. PubMed.

Recommends

Please login to recommend the paper.

Comments

  1. In this study, SantaCruz and colleagues have created an inducible mutant tau transgenic model, and observed the neuropathological consequences of strategically turning on and off tau expression for set periods. Profound forebrain neurodegeneration and memory loss by tau overexpression was observed. Remarkably, following termination of tau expression, tau hyperphosphorylation and tangle formation progressed while memory function recovered. These findings provide compelling evidence that neurofibrillary tangles do not directly serve a role in neuronal loss or cognitive impairment. This is consistent with a recent report by Peter Davies and colleagues that neurofibrillary pathology was not correlated with neuronal death in a human tau transgenic model displaying neurodegeneration (Andorfer et al., 2005). The study by SantaCruz et al. also provides the exciting prospective that recovery of cognitive function is possible even after significant progression of neurodegeneration. These findings have profound implications in the understanding of AD and other neurodegenerative disorders featuring tauopathy.

    References:

    Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci. 2005 Jun 1;25(22):5446-54. PubMed.

    View all comments by Li-Huei Tsai

  2. SantaCruz and colleagues manipulated transgenic tau levels using the tet-off system. Their results indicate that NFT accumulation is not sufficient to cause neuronal death and cognitive decline. This result was a bit of a surprise, because NFT formation increased even after transgenic tau expression was suppressed. Memory function also improved as suppressing tau expression halted brain atrophy. These results suggest that NFT formation, neuronal death, and cognitive decline may occur through different mechanisms in tauopathies. Moreover, it suggests that developing a tau aggregation inhibitor might not produce therapeutic benefits in such diseases. However, these results might very well be due to the effects of tau overexpression. Mandelkow’s group clearly showed that tau overexpression impaired anterograde axonal trafficking, which may cause synaptic dysfunction, eventually inducing memory failure and neuron death. When suppressing tau expression, axonal transport recovered. Memory function, therefore, might improve with the return of synaptic function.

    Once the tau concentration increases, conformational changes, which account for the earliest aberrations in tau in AD (Weaver et al., 2000), occur that produce tau by-products that are resistant to degradation. These residual products form tau fibrils, NFTs, thereby explaining why NFTs increase even after tau expression is suppressed, and they may generate tau oligomers that cannot be removed. Tau fibrils would then remain even after suppressing tau overexpression. In the authors’ mouse model, the effect of tau overexpression is commonly used to express phenotype; yet, patients with the P301L mutation do not have overexpressed mutant tau. Rather, mRNA levels of mutant tau are the same as wild tau levels, and soluble mutant tau levels are smaller than those for wild tau (Miyasaka et al., 2001). This mutant tau expression, albeit small, induces tauopathy. Thus, it is not overexpression, but tau mutations that provoke tauopathy (that is, NFT formation, neuronal loss, and dementia). Therefore, investigating the effects of tau mutation might provide insights into what is happening in patients with FTDP-17.

    References:

    Trojanowska K, Jaszewski B, Skupin J. Some problems concerning the determination of different corrinoids by the plate method with Escherichia coli 113-3. Acta Microbiol Pol B. 1975;7(2):103-10. PubMed.

    Miyasaka T, Morishima-Kawashima M, Ravid R, Kamphorst W, Nagashima K, Ihara Y. Selective deposition of mutant tau in the FTDP-17 brain affected by the P301L mutation. J Neuropathol Exp Neurol. 2001 Sep;60(9):872-84. PubMed.

    View all comments by Akihiko Takashima

  3. Neurofibrillary Tangles: Villain or Merely Vilified? What’s Next? TADDLs/TAuDDLs!
    For most investigators in the field of Alzheimer disease (AD), pathology has become equated with pathogenesis. As such, the two leading theories concerning the disease revolve around the amyloid-β of senile plaques and the phospho-tau of neurofibrillary tangles (NFTs). Contrasting this viewpoint, there a growing contingency suggesting that pathology is not central to pathogenesis; rather, pathology may even be the anti-pathogenesis and, rather than causing the disease, the pathology may be protecting from the disease (Rottkamp et al., 2002; Smith et al., 2002; Lee et al., 2005). A recent transgenic mouse study from Karen Ashe and colleagues (Santacruz et al., 2005) goes a long way toward bringing light to this specific issue. These studies quite convincingly demonstrate that NFT-like accumulations of phospho-tau are not associated with neurodegeneration, echoing a recent similar conclusion from the Peter Davies group (Andorfer et al., 2005). While these studies implicate NFTs as beneficial, since they are disconnected with cell death, better evidence for the exoneration of phospho-tau/NFTs in the disease process is provided by human studies (reviewed in Lee et al., 2005). For example, in patients with AD, phospho-tau and NFTs are unlikely to be factors in the neurodegenerative process since, while both the total number and length of microtubules are significantly and selectively reduced in pyramidal neurons, such decrements are unrelated to NFTs (Cash et al., 2003). This poses the question as to what causes the neurodegeneration. One suggestion is that NFTs sequester “abnormal” phospho-tau microaggregates, thereby rendering them harmless (Binder et al., 2005). Therefore, much like micro-aggregates of amyloid-β (ADDLs; Klein, 2002), the tau story has shifted to micro-aggregates of phospho-tau…let’s call them TADDLs or TAuDDLs (Tau-Derived Diffusible Ligands). The evidence for such TADDLs, much like their counterpart ADDLs (Lee et al., 2004), is scant but at least it keeps the prime suspects front and center. However, as we recently reviewed (Lee et al., 2005), there is far, far more evidence that phospho-tau, as TADDLs or NFTs, are a protective compensatory response mounted by neurons in an effort to stave off another driving pathogenic force. Indeed, oxidative damage not only chronologically precedes phospho-tau (Nunomura et al., 2000; Liu et al., 2005), but, supporting a protective response, such oxidative stress is significantly reduced in AD in neurons containing phospho-tau (Nunomura et al., 2001). Perhaps the time has come to reassess our old prejudices and exonerate the “villain.”

    References:

    Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci. 2005 Jun 1;25(22):5446-54. PubMed.

    Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW. Tau, tangles, and Alzheimer's disease. Biochim Biophys Acta. 2005 Jan 3;1739(2-3):216-23. PubMed.

    Cash AD, Aliev G, Siedlak SL, Nunomura A, Fujioka H, Zhu X, Raina AK, Vinters HV, Tabaton M, Johnson AB, Paula-Barbosa M, Avíla J, Jones PK, Castellani RJ, Smith MA, Perry G. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol. 2003 May;162(5):1623-7. PubMed.

    Klein WL. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int. 2002 Nov;41(5):345-52. PubMed.

    Lee HG, Casadesus G, Zhu X, Joseph JA, Perry G, Smith MA. Perspectives on the amyloid-beta cascade hypothesis. J Alzheimers Dis. 2004 Apr;6(2):137-45. PubMed.

    Lee HG, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, Takeda A, Nunomura A, Smith MA. Tau phosphorylation in Alzheimer's disease: pathogen or protector?. Trends Mol Med. 2005 Apr;11(4):164-9. PubMed.

    Liu Q, Smith MA, Avilá J, DeBernardis J, Kansal M, Takeda A, Zhu X, Nunomura A, Honda K, Moreira PI, Oliveira CR, Santos MS, Shimohama S, Aliev G, de la Torre J, Ghanbari HA, Siedlak SL, Harris PL, Sayre LM, Perry G. Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radic Biol Med. 2005 Mar 15;38(6):746-54. PubMed.

    Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, Smith MA. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol. 2000 Nov;59(11):1011-7. PubMed.

    Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001 Aug;60(8):759-67. PubMed.

    Rottkamp CA, Atwood CS, Joseph JA, Nunomura A, Perry G, Smith MA. The state versus amyloid-beta: the trial of the most wanted criminal in Alzheimer disease. Peptides. 2002 Jul;23(7):1333-41. PubMed.

    Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005 Jul 15;309(5733):476-81. PubMed.

    Smith MA, Casadesus G, Joseph JA, Perry G. Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med. 2002 Nov 1;33(9):1194-9. PubMed.

    View all comments by Akihiko Nunomura

  4. I found this paper fascinating and very intriguing, but could not determine whether the effects attributed to lowered tau levels (from the otherwise very high levels) are instead due to a neuroprotective effect of the drug used to control tau expression.

    View all comments by Michael Wolfe

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

Research Models

  1. rTg(tauP301L)4510

News

  1. No Toxicity in Tau’s Tangles?
  2. SfN: Return of the Other—Tau Is Back, Part 1
  3. Chicago: Tau and α-Synuclein Oligomers Follow Aβ Footsteps
  4. Las Vegas: Are Frontotemporal Dementia Models Fit for Pharma?
  5. San Francisco: Tau—Time to Shine as Therapeutic Target?
  6. The Many Faces of LRRK2
  7. Making It Stick—Tau Toxicity Linked to Aggregation Propensity
  8. Tau Timing: New Findings on Disease Progression, Clearance
  9. Heart and Brain—Oligomers Forge New Connection